Conduct AP-003 trials in COVID-19 patients in ex-North American territories
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 19 Jan 2021
- Due
- 31 Mar 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company is also considering conduct of AP-003 trials in COVID-19 patients in Q1-Q2 2021 in ex-North American territories”
What we found
Evidence strength A What the grades mean
The company reported in April 2021 that AP-003 was still in the preclinical stage of development and that its development path was being reassessed, indicating the trials did not occur as planned.
-
A BetterLife Pharma Inc. 6-K filed 2021-04-27
“AP-003 is currently in preclinical stage of development. The manufacturing and formulation work is currently ongoing. A pre-IND discussion has been conducted with the FDA for use of AP-003 inhalation in COVID-19.” ✓ confirmed on the page
Market reaction: the shares moved -0.0% against the S&P 500 over the three sessions around the disclosure (26 Apr 2021 to 29 Apr 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Conduct
- Deliverable
- AP-003 clinical trials
- Where
- ex-North American territories
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to health regulatory authorities’ approvals
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you BetterLife Pharma Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BETRF-022186 · Corrections policy